Rendered structure of the CTPS1 enzyme with dencatistat bound

Driving a step change in the treatment of cancer

Dencatistat is a first-in-class, oral, highly selective inhibitor of CTPS1, the enzyme cancer cells rely on to copy their DNA.

Three clinical trials in blood cancers and solid tumours€38M Series C, October 2025
CTPS1 converts UTP into CTP, which activated T cells need to divide. Dencatistat binds each of the four CTPS1 monomers, CTP output falls and T cell proliferation stops. UTP PRECURSOR CTP CTPS1 enzyme FOUR MONOMERS Activated T cells LYMPHOCYTES Dencatistat (STP938)MIMICS CTP, BINDS EACH MONOMER CTP SYNTHESIS BLOCKED Healthy non-blood cell CTPS2 KEEPS SUPPLYING CTP

One enzyme, one bottleneck

  1. Activated T cells need CTPTo divide, lymphocytes must build new DNA. The rate limiting step is CTPS1 turning UTP into CTP.
  2. Dencatistat binds each monomerThe molecule mimics CTP and sits in all four CTPS1 subunits, with more than 1,000-fold selectivity over CTPS2.
  3. Proliferation stops, other cells are sparedWithout CTPS1 the T cells can no longer divide, while cells outside the blood system keep making CTP through CTPS2.
CTP output100%
T cells1Dividing

A first-in-class CTPS1 inhibitor

Lead asset dencatistat (STP938)
Illustration of a lymphocyte

Step Pharma has unlocked the de novo pyrimidine synthesis pathway, a target that eluded cancer researchers for years.

Step Pharma has shown that cancers depend on CTPS1, and genomic loss of CTPS2 is a frequent event in cancer. That makes one oral, targeted drug relevant to blood cancers and to solid tumours.

Dencatistat is designed to kill cancer cells while sparing healthy cells, without the heavy side effects of many current and emerging therapies.

Read the CTPS1 science

Pipeline

Select a programme for trial details
IndicationArea
PreclinicalPhase 1Phase 2Phase 3
Monotherapy in adults with high risk ET who did not respond to, or had side effects from, current treatments. Started in 2026.
Five-year survival in peripheral T cell lymphoma remains below 30% and has not improved in over 20 years. A single arm Phase 2 could support accelerated approval.
Potential as monotherapy or in combination with available treatments, for the many patients who still relapse after CAR-T or bispecifics.
Synthetic lethality: tumours that lost CTPS2 depend entirely on CTPS1. A biomarker assay selects the patients most likely to benefit.
Preclinical data show strong synergy between dencatistat and emerging ATR, WEE1 and CHEK1 inhibitors.
Research programme

Why a new approach is needed

Figures from step-ph.com
<30%

five-year survival in peripheral T cell lymphoma, unchanged in over 20 years

20%

of all cancers may have lost CTPS2 and could benefit from selective CTPS1 inhibition

1,000×

selectivity of dencatistat for human CTPS1 over CTPS2

For patients

Three open clinical studies

We are bringing dencatistat to the patients who need it most, in blood cancers and solid tumours.

If you or someone you care for is living with essential thrombocythaemia, relapsed lymphoma or an advanced solid tumour, your doctor can check whether one of our studies is open near you.

Find our trials on ClinicalTrials.gov
Patient resting in a clinic

Partnering, investment and clinical collaboration

Backed by a €38M Series C led by V-Bio Ventures and an EIC grant for CTPS2-null gynaecological cancers.

Talk to Step Pharma